Enzastaurin Hydrochloride

N/A

Report date: 2023/05/05 17:34:56
NME

Base Information

Drug NameEnzastaurin Hydrochloride
Drug Alias Name恩扎滔林Enzastaurina恩扎妥林EnzastaurinumEnzastaurine +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsProtein kinase C beta inhibitors
TargetsPI3-kinase class IProtein kinase C beta
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursEhlers-Danlos Syndrome +[33] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[33] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesRumpus Therapeutics LLCDenovo Biopharma LlcXcelience Llc
Inactive CompaniesEli Lilly And CompanyNational Cancer InstituteAytu BioPharma Inc
Active IndicationsGlioblastomaLymphoma, Large B-Cell, Diffuse
Inactive IndicationsCNS Embryonal TumorSolid tumoursEhlers-Danlos Syndrome +[31] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG